Skip to content

Microbiologic and clinical evaluation of ultrasonic supragingival debridement combine with Erythritol Air-Polishing Powder versus ultrasonic supragingival debridement during supportive periodontal therapy in arches with zirconia or titanium implant-supported fixed complete dental prostheses (IFCDP): a randomized controlled clinical trial

Microbiologic and clinical evaluation of ultrasonic supragingival debridement combine with Erythritol Air-Polishing Powder versus ultrasonic supragingival debridement during supportive periodontal therapy in arches with zirconia or titanium implant-supported fixed complete dental prostheses (IFCDP): a randomized controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032431
Enrollment
Unknown
Registered
2020-04-28
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biological complications of implants

Interventions

control group: ultrasonic supragingival debridement
experimental group:ultrasonic supragingival debridement combine with Erythritol Air-Polishing Powder

Sponsors

Peking University Hospital of Stomatology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Edentulous jaw restored with full-arch fixed implant-supported rehabilitation; (2) General health,ASA I~II classification of American Society of Anesthesiologists; (3) Age over 18 years old; (4) Good oral hygiene and good compliance; (5) Signing an informed written consent.

Exclusion criteria

Exclusion criteria: (1) Poor oral hygiene and uncontrolled peridontitis; (2) Antibiotics use in the past 3 months; (3) Systemic disease: uncontrolled diabetes mellitus, cardiovascular disease, disease of immune system, blood disorders such as coagulation disorders, severe osteoporosis; (4) Long-term medication users: steroid, anti-epileptic drug, biophosphonates; (5) HIV infection, Hepatitis B, syphilis; (6) Bruxism; (7) Smoker; (8) Uncontrolled infection in the area intended for implant placement or other areas; (9) Maxillofacial tumor; (10) Face-neck radiotherapy; (11) Mental illness or high expectations.

Design outcomes

Primary

MeasureTime frame
plaque index;bleeding index;probing depth;marginal bone loss;Assessment of microbial species;

Secondary

MeasureTime frame
plaque staining;

Countries

China

Contacts

Public ContactJianxia Hou

Peking University Hospital of Stomatology

jxhou@163.com+86 13683696349

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026